{"id":"rosiglitazone-xr","safety":{"commonSideEffects":[{"rate":"~2-3 kg average","effect":"Weight gain"},{"rate":"4-5%","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"~9%","effect":"Upper respiratory tract infection"},{"rate":"~5%","effect":"Headache"},{"rate":"~3%","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL121","moleculeType":"Small molecule","molecularWeight":"357.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to PPAR-γ in adipose tissue and muscle, rosiglitazone enhances insulin signaling and glucose uptake, reducing hepatic glucose production and improving peripheral insulin sensitivity. This leads to decreased fasting and postprandial blood glucose levels in patients with type 2 diabetes. The XR (extended-release) formulation provides once-daily dosing convenience.","oneSentence":"Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:59.403Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT00490568","phase":"PHASE3","title":"Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-08-08","conditions":"Alzheimer's Disease","enrollment":1461},{"nctId":"NCT00550420","phase":"PHASE3","title":"Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-10-01","conditions":"Alzheimer's Disease","enrollment":331},{"nctId":"NCT00468897","phase":"PHASE1","title":"A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-21","conditions":"Alzheimer's Disease","enrollment":50},{"nctId":"NCT00733785","phase":"PHASE1","title":"PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-08-13","conditions":"Alzheimer's Disease","enrollment":60},{"nctId":"NCT00428090","phase":"PHASE3","title":"Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-27","conditions":"Alzheimer's Disease","enrollment":862},{"nctId":"NCT00688207","phase":"PHASE1","title":"Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04","conditions":"Alzheimer's Disease","enrollment":14},{"nctId":"NCT00379600","phase":"PHASE2","title":"The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":"Arthritis, Rheumatoid","enrollment":96},{"nctId":"NCT00884533","phase":"PHASE1","title":"QTc Study of Rosi XR in Healthy Volunteers","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":""},{"nctId":"NCT00334568","phase":"PHASE2","title":"Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Alzheimer's Disease","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","Rosiglitazona"],"phase":"marketed","status":"active","brandName":"Rosiglitazone XR","genericName":"Rosiglitazone XR","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}